Hengrui Yuanzheng Establishes Ruiliyuan Biotechnology to Expand IVD and Cell Therapy Portfolio

Source: Securities Times

People's Finance News, September 18th: According to Qichacha APP, recently, Shanghai Rui Liyuan Biotechnology Co., Ltd. was established, with Hu Hongcheng as the legal representative, a registered capital of 10 million yuan, and a business scope including the development of human gene diagnosis and treatment technology; the development and application of human stem cell technology; the operation of Class III medical devices; the sales of electronic products, etc. Qichacha's equity penetration shows that the company is wholly owned by Hengrui Yuanzheng (Shanghai) Biotechnology Co., Ltd.Hengrui Pharma(600276) Sun Piaoyang serves as the chairman of the latter.